(2-propyl-1H-indol-3-yl)methanol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (2-propyl-1H-indol-3-yl)methanol
• 化学式: C₁₂H₁₅NO
• 分子量: 189.25
• InChiKey: LXGIKKDAIHJCQO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  36
• 氢给体数：
  2
• 氢受体数：
  1

文献信息

• DIINDOLYLMETHANE, PRECURSOR AND DERIVATIVES THEREOF IN PREPARATION OF MEDICAMENTS FOR TREATING LIVER DISEASES
  申请人：Nanjing University

  公开号：EP2606887A1

  公开（公告）日：2013-06-26

  This invention relates to biopharmaceutical technology, specifically to the application of 3,3'-Diindolylmethane, indole-3-carbinol, and derivatives thereof in the preparation of drugs for treating such hepatic diseases as viral hepatitis, alcoholic hepatitis, drug-induced hepatitis, fatty liver, hepatic fibrosis and hepatic cirrhosis. The said indole-3-carbinol, diindolylmethane and derivatives thereof can effectively protect the human body from the damage resulting from ROS by inhibiting ROS-induced activation of hepatic stellate cells and correlated expression of collagen, which consequently ameliorates degree of hepatic fibrosis. Therefore they can be used in treatment of diseases related to hepatic fibrosis. As is verified in the animal models of hepatic fibrosis, the said indole-3-carbinol, diindolylmethane and derivatives thereof present excellent therapeutic effect and positive application prospect.

  本发明涉及生物制药技术，具体涉及3,3'-二吲哚甲烷、吲哚-3-甲醇及其衍生物在制备治疗病毒性肝炎、酒精性肝炎、药物性肝炎、脂肪肝、肝纤维化和肝硬化等肝病药物中的应用。上述吲哚-3-甲醇、二吲哚甲烷及其衍生物可通过抑制 ROS 诱导的肝星状细胞活化和胶原蛋白的相关表达，有效保护人体免受 ROS 的损害，从而改善肝纤维化程度。因此，它们可用于治疗与肝纤维化有关的疾病。正如在肝纤维化动物模型中验证的那样，上述吲哚-3-甲醇、二吲哚甲烷及其衍生物具有极佳的治疗效果和积极的应用前景。
• Estrogenic substances combined with cruciferous indole compounds
  申请人：——

  公开号：US20020058648A1

  公开（公告）日：2002-05-16

  Provided herein are medicinal compositions of matter that comprise an estrogenic medication component and a cruciferous indole component (indole 3-carbinol, diindolylmethane, or any derivative thereof. Through use of the compositions of the invention a heretofore unobserved synergy is observed in the treatment of perimenopause, menopause or any other cause of ovarian failure. The invention also provides procedures for administering the composition to a patient who is afflicted with perimenopause, menopause or any other cause of ovarian failure.

  本发明提供的药物组合物包含雌激素药物成分和十字花科吲哚成分（吲哚-3-甲醇、二吲哚甲烷或其任何衍生物）。通过使用本发明的组合物，在治疗围绝经期、更年期或任何其他原因引起的卵巢功能衰竭时，可以观察到一种迄今为止尚未观察到的协同作用。本发明还提供了向患有围绝经期、更年期或任何其他原因引起的卵巢功能衰竭的患者施用本发明组合物的程序。
• SUBSTITUTED ANALOGS OF INDOLE-3-CARBINOL AND OF DIINDOLYMETHANE AS ANTIESTROGENS
  申请人：THE TEXAS A&M UNIVERSITY SYSTEM

  公开号：EP0971890B1

  公开（公告）日：2002-11-27
• IMPROVED ANTITUMORAL COMBINATIONS CONTAINING ET-743 AND A CRUCIFEROUS INDOLE COMPOUND
  申请人：Pharma Mar, S.A.U.

  公开号：EP1675592A1

  公开（公告）日：2006-07-05
• Antitumoral combinations containing et-743 and a cruciferous and a cruciferous indole compound
  申请人：Donald Sarah

  公开号：US20070004691A1

  公开（公告）日：2007-01-04

  Administration of a cruciferous indole compound can reduce undesirable toxic side effects inherent in the anti-tumor therapy with ET-743 before during or after administration of the ET-743.